Assembly Biosciences (NASDAQ:ASMB) Stock Rating Lowered by StockNews.com

Assembly Biosciences (NASDAQ:ASMB) was downgraded by StockNews.com from a “buy” rating to a “hold” rating in a research report issued to clients and investors on Monday.

Separately, HC Wainwright reiterated a “neutral” rating on shares of Assembly Biosciences in a research report on Monday.

Assembly Biosciences Price Performance

ASMB opened at $11.42 on Monday. The stock has a market capitalization of $72.59 million, a P/E ratio of -1.70 and a beta of 0.62. The company’s 50 day simple moving average is $12.77 and its 200-day simple moving average is $15.05. Assembly Biosciences has a one year low of $10.27 and a one year high of $19.93.

Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings data on Thursday, March 20th. The biopharmaceutical company reported ($1.57) EPS for the quarter, beating analysts’ consensus estimates of ($1.75) by $0.18. The firm had revenue of $7.36 million for the quarter, compared to analyst estimates of $7.05 million. Assembly Biosciences had a negative return on equity of 121.46% and a negative net margin of 144.05%. As a group, analysts anticipate that Assembly Biosciences will post -6.87 EPS for the current year.

Insider Buying and Selling at Assembly Biosciences

In related news, Director Michael Houghton acquired 3,202 shares of the company’s stock in a transaction that occurred on Monday, December 30th. The stock was acquired at an average price of $15.61 per share, for a total transaction of $49,983.22. Following the completion of the acquisition, the director now owns 3,202 shares of the company’s stock, valued at $49,983.22. This trade represents a ∞ increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Insiders own 5.10% of the company’s stock.

Hedge Funds Weigh In On Assembly Biosciences

Institutional investors have recently modified their holdings of the stock. JPMorgan Chase & Co. raised its position in shares of Assembly Biosciences by 5,137.3% in the 3rd quarter. JPMorgan Chase & Co. now owns 3,509 shares of the biopharmaceutical company’s stock valued at $53,000 after acquiring an additional 3,442 shares during the period. Palumbo Wealth Management LLC acquired a new stake in Assembly Biosciences in the fourth quarter worth $180,000. Marshall Wace LLP boosted its position in shares of Assembly Biosciences by 16.5% during the fourth quarter. Marshall Wace LLP now owns 14,823 shares of the biopharmaceutical company’s stock worth $234,000 after purchasing an additional 2,098 shares in the last quarter. FMR LLC grew its holdings in shares of Assembly Biosciences by 29.7% in the 3rd quarter. FMR LLC now owns 15,855 shares of the biopharmaceutical company’s stock valued at $240,000 after buying an additional 3,635 shares during the period. Finally, Man Group plc bought a new stake in shares of Assembly Biosciences in the 4th quarter valued at $309,000. 19.92% of the stock is currently owned by institutional investors and hedge funds.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc, a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial.